Perspectives on current survival and new developments in AML
Author:
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 34 (1) , 101248
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Will new agents impact survival in AML?Best Practice & Research Clinical Haematology, 2019
- Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year periodBlood, 2019
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Acute Myeloid Leukemia: A Concise ReviewJournal of Clinical Medicine, 2016
- Therapeutic Advances in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2011
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 TrialJournal of Clinical Oncology, 2011
- Acute promyelocytic leukemia: from highly fatal to highly curableBlood, 2008
- Drug therapy for acute myeloid leukemiaBlood, 2005
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003